Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

NCT07647016 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab Deruxtecan and ivonescimab

Sponsor

Fudan University